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Background: Ki-67 is a robust predictive/prognostic marker in prostate cancer; however, tumor heterogeneity in prostate biopsy
samples is not well studied.Methods: Using an MRI/US fusion device, biopsy cores were obtained systematically and by targeting
when indicated by MRI. Prostate cores containing cancer from 77 consecutive men were analyzed. The highest Ki-67 was used
to determine interprostatic variation. Ki-67 range (highest minus lowest) was used to determine intraprostatic and intralesion
variation. Apparent diffusion coefficient (ADC) values were evaluated in relation to Ki-67. Results: Interprostatic Ki-67 mean ±
standard deviation (SD) values for NCCN low (L), intermediate (I), and high (H) risk patients were 5.1 ± 3.8%, 7.4 ± 6.8%, and
12.0 ± 12.4% (ANOVA 𝑃 = 0.013). Intraprostatic mean ± SD Ki-67 ranges in L, I, and H risk patients were 2.6 ± 3.6%, 5.3 ± 6.8%,
and 10.9 ± 12.3% (ANOVA 𝑃 = 0.027). Intralesion mean ± SD Ki-67 ranges in L, I, and H risk patients were 1.1 ± 0.9%, 5.2 ± 7.9%,
and 8.1 ± 10.8% (ANOVA 𝑃 = 0.22). ADC values at Ki-67 > and <7.1% were 860 ± 203 and 1036 ± 217, respectively (𝑃 = 0.0029).
Conclusions:High risk patients have significantly higher inter- and intraprostatic Ki-67 heterogeneity. This needs to be considered
when utilizing Ki-67 clinically.
1. Introduction
Progress in multiparametric MRI imaging has improved our
ability to visualize specific target lesions within the prostate.
Ultrasound/MRI fusion devices allow for targeted biopsies
of these specific MRI defined lesions. These advances create
an opportunity to evaluate biomarkers from specific target
lesions for integration into radiation treatment stratification.
The Ki-67 protein functions as a nuclear antigen that is
only expressed in proliferating cells. It is a marker of the
growth fraction in malignant tissue [1–3]. It is determined
via immunohistochemistry and expressed as a percentage of
cells showing activity in a given tissue sample (e.g., Ki-67 of
10% equates to 10% of the cells expressing the antigen). It is
a promising biomarker in prostate cancer with independent
predictive/prognostic value following radiotherapy [4–6]. A
range of percentage cut points has correlated with outcomes
but has not been prospectively validated [7–11]. One limita-
tion to integrating biomarkers into clinical practice is being
able to account for tumor heterogeneity. Ki-67 heterogeneity
has been acknowledged in liver, breast, and several other
cancers but has not been well studied in prostate cancer [12–
14]. Previous studies have used the highest Ki-67 level found
on routine systematic prostate biopsy cores but have not eval-
uated variation based onMRI defined lesions. Understanding
which MRI defined lesions harbor the highest Ki-67 would
be helpful in directing targeted biopsies and informing future
clinical trial design. In this studywe evaluatedKi-67 variation
across NCCN risk groups (interprostatic), within individual
prostates (intraprostatic), andwithinMRI-defined individual
lesions (intralesion).We also looked at how the highest Ki-67
per patient is related to themost dominant lesion onMRI and
whether apparent diffusion coefficient (ADC) values based
on diffusion weighted imaging correlate with Ki-67.
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Table 1: Patient characteristics.
Total NCCN low NCCN inter NCCN high
Number of patients 77 31 30 16
Mean age (years) 66.8 65.7 65.8 70.6
Age range 44–82 44–76 51–82 58–82
Mean PSA (ng/dL) 7.7 4.9 7.22 14.1
PSA range 0.51–36.2 0.51–9.7 0.8–15 2.3–36.2
T1A-C 63 (82%) 30 (97%) 28 (93%) 5 (31%)
T2A 14 (18%) 1 (3%) 2 (7%) 11 (69%)
T2B+ 0 0 0 0
Gleason 6 34 (44%) 31 (100%) 3 (10%) 0
Gleason 7 27 (35%) 0 27 (90%) 0
Gleason 8–10 16 (21%) 0 0 16 (100%)
Biopsy-positive cores with Ki-67 stain 268 66 105 97
Mean cores per patient 3.48 2.13 3.50 6.06
Intraprostatic: patients with ≥2 Ki-67 values 47 16 19 12
Intralesion: lesions with ≥2 MRI targeted cores 38 7 15 16
2. Materials and Methods
This was an IRB approved retrospective study. Charts were
reviewed for patients who were referred to the Department
of Urology for Artemis (ultrasound/MRI fusion) guided
prostate biopsies. All men underwent 3T multiparametric
MRI prior to biopsy. Lesions identified on MRI imaging
were segmented as regions of interest. The MRI was then
fused with ultrasound at the time of the biopsy. Systematic
Artemis assisted biopsies were performed first and, when
MRI indicated a lesion, targeted biopsies were performed.
Targeted biopsies were taken every 3–5mm through a target.
Patients were stratified by NCCN Risk criteria using
pretreatment PSA, T stage, and Gleason score. Pathology
reports were reviewed for Gleason score and Ki-67 (%) for
each of the positive prostate cancer cores. The highest Ki-
67 documented for each patient was used for interprostatic
variation. For patients with ≥2 positive biopsies variation
within each prostate (intraprostatic) was performed by taking
the highest Ki-67 minus the lowest Ki-67. Intralesion analysis
was carried out when multiple biopsy cores were taken from
one MRI-defined lesion using the same high minus low Ki-
67 method used for intraprostatic variation.The index lesion
was defined as the one with the maximum tumor diameter as
measured on T2 weighted MRI. The ADC values of lesions
as determined from diffusion weighted imaging were also
examined to determine if there was a correlation with Ki-67.
2.1. Ki-Staining Methods. Paraffin-embedded sections were
cut at 4𝜇m thickness and paraffin removed with xylene
and rehydrated through graded ethanol. Endogenous per-
oxidase activity was blocked with 3% hydrogen peroxide in
methanol for 10min. Heat-induced antigen retrieval (HIER)
was carried out for all sections in 0.01M Citrate buffer,
pH = 6.00, using a vegetable steamer at 95∘C for 25min.
The slides were then stained with mouse monoclonal Ki-
67, clone MIB1 (DakoCytomation, M7240), for 45min at
room temperature. The primary antibody was diluted with
calcium chloride to 1/100 concentration. The signal was
detected using the MACH 2 Mouse HRP Polymer (Biocare
Medical, MHRP520). All sections were visualized with the
diaminobenzidine reaction and counterstained with hema-
toxylin.
2.2. Statistical Analysis. One-way analysis of variance
(ANOVA) was used to evaluate significant differences
between the means of the different NCCN Risk groups.
Statistical significance was set at a 𝑃 value < 0.05.
3. Results
77 men were identified who had Artemis guided positive
prostate biopsies with Ki-67 staining reported. The mean
patient age was 67, the mean PSA was 7.7 ng/dL, and all
patients had a clinical stage of T2a or lower (see Table 1).
Interprostatic variation showed the Ki-67 ranged from 1
to 50% with an overall mean of 7.4%. Ki-67 was significantly
different between NCCN risk groups with mean ± standard
deviation (SD) values for low, intermediate, and high risk
patients of 5.1% ± 3.8%, 7.4% ± 6.8%, and 12.0% ± 12.4%
(ANOVA 𝑃 = 0.013) (Figure 1). It was also significantly
different for Gleason scores of 6, 7, and ≥8, with Ki-67 means
of 5.0% ± 3.8%, 7.7% ± 7.0%, and 12.0% ± 12.4% (𝑃 = 0.01,
Figure 1). Differences by T stage and PSAwere not significant
(Figure 1).
Intraprostatic variation was assessed on 47 patients with
≥2 biopsy-positive cores with Ki-67 quantified. Mean ± SD
Ki-67 variation (the highest Ki-67 minus the lowest Ki-67) in
low, intermediate, and high risk patients was 2.6 ± 3.6%, 5.3 ±
6.8%, and 10.9 ± 12.3% (ANOVA 𝑃 = 0.027). Figure 2 shows
the distribution of Ki-67 values and means for each patient
per risk group showing a greater heterogeneity of Ki-67 in
higher risk patients.
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Figure 1: Ki-67% at (a) increasing PSA ranges, (b) clinical T stages, (c) increasing Gleason scores, and (d) NCCN risk groups.
Intralesion variation was assessed on 38MP-MRI defined
lesions that had≥2 cores fromeach lesionwithKi-67 staining.
Intralesion mean ± SD Ki-67 variation (the highest Ki-67
minus the lowest Ki-67) in low, intermediate, and high risk
patients was 1.1 ± 0.9%, 5.2 ± 7.9%, and 8.1 ± 10.8% (ANOVA
𝑃 = 0.22).
10 patients had 2 or more lesions identified on MP-MRI.
The dominant lesion harbored the highest Ki-67 30% of
the time (Table 2). The dominant and nondominant lesion
contained the same Ki-67 in 30% and in 40% of patients the
highest Ki-67 was seen in a nondominant lesion.
Ki-67 cut-off levels of <3.5% and >7.1% were used based
on retrospective validation of these values in predicting
outcomes following definitive radiation treatment in patients
treated on two separate RTOG trials [15, 16]. The mean ± SD
ADC in patients with a Ki-67 < 3.5% (𝑛 = 31) was 1075 ± 205
and in patients with a Ki-67 > 3.5% (𝑛 = 48) was 940 ± 224
(𝑃 = 0.0039). For patients with a Ki-67 < 7.1% (𝑛 = 60) the
mean ADC was 1036 ± 217 while patients with values > 7.1%
had a mean ADC of 860 ± 203 (𝑃 = 0.0029).
4. Discussion
NCCN risk grouping (clinical T stage, Gleason score, and
PSA) is commonly used to determine radiation treatment
options. While this risk stratification is clinically helpful, it
is also limited in that patients in each risk category are not
homogeneous. Integration of biomarkers into existing strat-
ification schemes could help personalize treatment options.
Ki-67 is a robust biomarker that has been evaluated in three
separate RTOG trials with cut-offs of 3.5%, 6.2%, and 7.1%
being independent predictors of outcomes [11, 15–17]. These
studies used the highest Ki-67 based on standard systematic
prostate biopsy cores. It is possible that this method actually
underscores patients, as a standard biopsy may not obtain
tissue from areas of the highest risk. To integrate these
findings into future clinical studies one needs to consider the
impact of tumor heterogeneity so one can be confident that
patients are appropriately stratified.
Using information from multiparametric MRI and tar-
geted biopsies we were able to demonstrate a number of
things. Overall we foundKi-67 levels aremore heterogeneous
with increasingNCCN risk group.This observation is consis-
tent with other studies which have shown increased Ki-67 in
patients with higher Gleason scores [18, 19]. We also found
significant heterogeneity in our intraprostatic and intralesion
analysis. Higher risk groups consistently showed a greater
degree of variation within each prostate/lesion, but even low
risk patients had differences as high as 14% between two
locations within a prostate.
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Figure 2:The Ki-67% in each lesion for the 47 patients with ≥2 lesions is demonstrated by each square along with means designated by a red
“x.” Patients are stratified by NCCN Risk Group.
Table 2: Comparison of Ki-67% in dominant and nondominant lesions, stratified by NCCN risk group.
Pt # Dominant lesion Nondominant High Ki-67 in dominant lesion
MRI lesion (cm) Ki-67 (%) GS MRI lesion (cm) Ki-67 (%) GS
High
7 2.3 7 4 + 5 1.9 7 4 + 4 Yes∗
11 1.6 8 3 + 4 0.9 10 3 + 5 No
54 3.1 5 5 + 4 1.3 2 5 + 4 Yes
73 1.9 20 4 + 5 0.8 15 3 + 5 Yes
74 1.1 50 4 + 5 0.5 5 3 + 4 Yes
Inter
14 1.3 5 3 + 4 0.9 10 3 + 4 No
27 1 1 3 + 3 0.7 1 3 + 3 Yes∗
58 2.2 1 3 + 3 2 5 3 + 4 No
Low 20 1.3 1 3 + 3 0.8 1 3 + 3 Yes
∗
77 1.1 3 3 + 3 0.9 5 3 + 3 No
∗High Ki-67 in nondominant lesion also.
Given the variability within the prostate we tried to
determine if the index lesion was most likely to harbor the
highest Ki-67. We found that this was the case in only 3/10
cases. This suggests that relying on a biopsy only from the
index lesion may not be a reliable representation of the
highest Ki-67 within the entire gland.
Further complicating things is the high variability within
an individual lesion. While 8% variability (the highest Ki-
67 minus lowest Ki-67) seems low the cut-offs for Ki-67
levels that stratify patients range between 3.5% and 7.1%. So
a difference of 8% is actually very meaningful. The concept
of tumor heterogeneity is certainly not novel but this study
emphasizes the importance of not relying too heavily on a
single core. A more representative picture of the tumor, at
least with respect to Ki-67, is better achieved with multiple
cores taken from a single lesion. It is beyond the scope of this
paper to provide an answer to how many cores are needed to
accurately depict the totality of tumor heterogeneity.
Prostate Cancer 5
Given the complexities with accurately portraying tumor
heterogeneity based off of biopsy samples we asked whether
the average ADC value correlates with Ki-67 values. This
would be meaningful because it would be much simpler to
use an ADC value generated from a computer to stratify
a patient rather than doing multiple targeted biopsies. We
found that there was a significant correlation between ADC
values within clinically relevant Ki-67 groupings (i.e., <3.5%,
3.5–7.1%, and >7.1%). There is overlap between these values
but their means are significantly different from one another.
While this is an interesting correlation, validation on a larger
cohort is needed and ultimately prospective data is needed
to determine if ADC values can independently predict
outcomes in prostate cancer.
5. Conclusions
This study provides the first evidence of the magnitude
of tumor heterogeneity of the most well studied tumor
biomarker in radiation therapy for prostate cancer. Inte-
gration of Ki-67 into future risk stratification schemes for
clinical trials needs to incorporate issues related to tumor
heterogeneity in order to accurately stratify patients.
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